{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He X"],"funding":["National Science Fund for Distinguished Young Scholars","Fudan-SIMM Joint Research Fund","National Natural Science Foundation of China"],"pagination":["1701070"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5979633"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(5)"],"pubmed_abstract":["Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive malignancy with a five year survival rate of <5%. The aberrant expression of extracellular matrix (ECM) in the tumor stroma forms a compact physical barrier, which that leads to insufficient extravasation and penetration of nanosized therapies. To overcome the severe resistance of PDAC to conventional therapies, a sequentially triggered nanoparticle (aptamer/cell-penetrating peptide-camptothecin prodrug, i.e., Apt/CPP-CPTD NPs) with tumor penetration and intelligent drug release profile is designed. An ECM component (tenescin-C) targeting aptamer (GBI-10) is modified onto stroma-permeable cell-penetrating peptide (CPP) for the in vivo CPP camouflage and PDAC-homing. In PDAC stroma, tenascin-C can detach GBI-10 from CPP and expo"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy."],"pmcid":["PMC5979633"],"funding_grant_id":["81373355","FU-SIMM20174009","81425023"],"pubmed_authors":["Chen Q","Liu L","Li C","Zhang Y","Lu Y","He X","Ruan C","Sun T","Jiang C","Chen X","Guo Q"],"additional_accession":[]},"is_claimable":false,"name":"Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy.","description":"Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive malignancy with a five year survival rate of <5%. The aberrant expression of extracellular matrix (ECM) in the tumor stroma forms a compact physical barrier, which that leads to insufficient extravasation and penetration of nanosized therapies. To overcome the severe resistance of PDAC to conventional therapies, a sequentially triggered nanoparticle (aptamer/cell-penetrating peptide-camptothecin prodrug, i.e., Apt/CPP-CPTD NPs) with tumor penetration and intelligent drug release profile is designed. An ECM component (tenescin-C) targeting aptamer (GBI-10) is modified onto stroma-permeable cell-penetrating peptide (CPP) for the in vivo CPP camouflage and PDAC-homing. In PDAC stroma, tenascin-C can detach GBI-10 from CPP and expo","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 May","modification":"2025-04-26T08:26:36.739Z","creation":"2019-03-26T23:40:35Z"},"accession":"S-EPMC5979633","cross_references":{"pubmed":["29876225"],"doi":["10.1002/advs.201701070"]}}